Acurx Pharmaceuticals, Inc. (ACXP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Acurx Pharmaceuticals reported revenue of $0. Net income was -$8.0M, or -$5.32 per diluted share. Operating activities generated -$6.8M of cash. At fiscal year end, Acurx Pharmaceuticals held $7.7M in total assets against $2.4M in total liabilities.
Open the full interactive Acurx Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Acurx Pharmaceuticals Key Stats
| Share Price | $1.20 |
|---|---|
| Market Cap | $5.1M |
| 52-Week Range | $1.20 – $7.59 |
| Shares Outstanding | 4.3 million (basic, 2026 Q2) |
Acurx Pharmaceuticals Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | — | — | — | — | -$8.1M |
| Pre-Tax Income | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| Income Tax | — | $0 | — | — | — |
| Net Income | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M |
| Diluted EPS | -$29.80 | -$22.40 | -$23.00 | -$17.40 | -$5.32 |
Acurx Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.0M | -$1.6M | -$1.7M | -$2.3M |
| Diluted EPS | -$1.23 | -$1.05 | -$0.62 | -$0.53 |
Acurx Pharmaceuticals Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Total Assets | $13.3M | $9.4M | $7.7M | $3.9M | $7.7M |
| Current Liabilities | $843,909 | $2.1M | $3.0M | $3.2M | $2.4M |
| Total Liabilities | $843,909 | $2.1M | $3.0M | $3.2M | $2.4M |
| Shareholders' Equity | $12.4M | $7.3M | $4.7M | $615,121 | $5.3M |
Acurx Pharmaceuticals Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M |
| Cash From Financing | $14.8M | $3.7M | $8.2M | $6.6M | $10.6M |
Figures from Acurx Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Acurx Pharmaceuticals financials page for every line item.
Acurx Pharmaceuticals Company Profile
| Ticker | ACXP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Staten Island, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001736243 |
Frequently Asked Questions
What was Acurx Pharmaceuticals' revenue in fiscal 2025?
Acurx Pharmaceuticals (ACXP) reported revenue of $0 for fiscal 2025.
What is Acurx Pharmaceuticals' annual revenue history?
Acurx Pharmaceuticals' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Acurx Pharmaceuticals' net income in fiscal 2025?
Acurx Pharmaceuticals reported net income of -$8.0M for fiscal 2025.
What was Acurx Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Acurx Pharmaceuticals' diluted EPS was -$5.32 for fiscal 2025 (adjusted for any later stock splits).
What was Acurx Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Acurx Pharmaceuticals reported revenue of $0.
How many shares of Acurx Pharmaceuticals are outstanding?
Acurx Pharmaceuticals reported a weighted average of 4.3 million basic shares outstanding in 2026 Q2.
What is Acurx Pharmaceuticals' market cap?
Based on its latest closing price, Acurx Pharmaceuticals (ACXP) has a market capitalization of about $5.1M.
When does Acurx Pharmaceuticals' fiscal year end?
Acurx Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Acurx Pharmaceuticals headquartered?
Acurx Pharmaceuticals lists its business address in Staten Island, New York in its SEC filings.